《医疗器械》中国篇(英)

CHAMBERS GLOBAL PRACTICE GUIDESHealthcare: Medical Devices 2024Definitive global law guides offering comparative analysis from top-ranked lawyersChina: Law and Practice Alan Zhou, Coco Fan and Kelly Cao Global Law OfficeCHINA2CHAMBERS.COMLaw and PracticeContributed by: Alan Zhou, Coco Fan and Kelly Cao Global Law OfficeContents1. Applicable Product Safety Regulatory Regimes p.51.1 Medical Devices p.51.2 Healthcare Products p.61.3 Medicines p.71.4 Technologies and Digital Health p.81.5 Borderline Products p.92. Commercialisation and Product Life Cycle p.102.1 Design and Manufacture p.102.2 Corporate Social Responsibility, the Environment and Sustainability p.122.3 Advertising and Product Claims p.132.4 Marketing and Sales p.152.5 Internationalisation p.182.6 Post-marketing Obligations, Including Corrective Actions and Recalls p.203. Regulator Engagement and Enforcement p.223.1 Regulatory Authorities p.223.2 Regulatory Enforcement Mechanisms p.234. Liability p.234.1 Product Safety Offences p.234.2 Product Liability p.244.3 Judicial Requirements p.254.4 Costs p.254.5 Product-Related Contentious Matters p.264.6 Class Actions, Representative Actions or Co-ordinated Proceedings p.264.7 ADR Mechanisms p.274.8 Interrelation Between Liability Mechanisms p.275. Applicable Product Safety Regulatory Regimes p.285.1 Policy Development p.285.2 Legislative Reform p.295.3 Impact of Artificial Intelligence p.30CHINA Law and PracticeContributed by: Alan Zhou, Coco Fan and Kelly Cao, Global Law Office 3CHAMBERS.COMGlobal Law Office dates back to the establish-ment of China’s Legal Consultant Office of the Council for the Promotion of International Trade in 1979. GLO has become one of the largest and leading Chinese law firms, with more than 500 lawyers practising in its Beijing, Shanghai, Shenzhen, and Chengdu offices. Its life scienc-es and healthcare (L&H) practice group is one of the earliest L&H teams in China, having pro-vided “one-stop” legal services for every area of the L&H industry, including M&A, investment and funding, licence in and out, daily operation, IP protection, and advice on compliance includ-ing internal and government investigations as well as anti-bribery matters and dispute settle-ment. Under a changing regulatory environment, GLO’s L&H team has the perfect combination of international experience and local know-how to support various innovation and pilot projects, including digital healthcare and MAH/CMAH trial cases. GLO’s L&H team deeply participates in the formulation of local codes of conduct and benchmark policies/rules.AuthorsAlan Zhou is the leading partner of the life sciences and healthcare (L&H) practice group at Global Law Office, with a strong background in L&H. Mr Zhou routinely represents multinational corporations, well-known Chinese state-owned and private enterprises, and private equity/venture capital funds in the L&H area. He has been engaged by local authorities and industrial associations to advise on legislation and i

立即下载
医药生物
2024-10-14
32页
1.5M
收藏
分享

《医疗器械》中国篇(英),点击即可下载。报告格式为PDF,大小1.5M,页数32页,欢迎下载。

本报告共32页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
本报告共32页,只提供前10页预览,清晰完整版报告请下载后查看,喜欢就下载吧!
立即下载
水滴研报所有报告均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
相关图表
医药板块估值及估值溢价率图8:医药子板块估值
医药生物
2024-10-14
来源:医药行业2024年10月月报:看好超预期%2b超跌
查看原文
2024年9月医药板块涨幅TOP10标的图6:2024年9月医药板块跌幅TOP10标的
医药生物
2024-10-14
来源:医药行业2024年10月月报:看好超预期%2b超跌
查看原文
2022年以来中信医药和沪深300比较(累计收益,%)图2:2024年9月医药指数涨跌幅在中信一级行业排名第15名(%)
医药生物
2024-10-14
来源:医药行业2024年10月月报:看好超预期%2b超跌
查看原文
康方生物2021-2024H1收入和归母净利润(单位:亿元)图:康方生物2021-2024H1各费用(单位:亿元)
医药生物
2024-10-14
来源:医药生物行业创新药板块投资策略:看好头部biopharma,实现盈利叠加管线兑现
查看原文
表达量≥10% PDAC患者中,cORR为38.9%;在CLDN18.2表达量≥10%的胃癌患者,ORR为30.8%,mPFS为3.5个月,疗效优异。而
医药生物
2024-10-14
来源:医药生物行业创新药板块投资策略:看好头部biopharma,实现盈利叠加管线兑现
查看原文
2019-2024H1信达生物各费用(单位:亿元)图:2019-2024H1信达生物营业收入和利润(单位:亿元)
医药生物
2024-10-14
来源:医药生物行业创新药板块投资策略:看好头部biopharma,实现盈利叠加管线兑现
查看原文
回顶部
报告群
公众号
小程序
在线客服
收起